For patients with metastatic renal cell carcinoma (mRCC) and progression during or after one to two prior lines of therapy, including one immune checkpoint inhibitor (ICI), tivozanib has efficacy, according to a study published online Sept. 13 in The Lancet to coincide with the annual meeting of the European Society for Medical Oncology, held from Sept. 13 to 17 in Barcelona, Spain.
Tivozanib has efficacy in advanced renal cell carcinoma post-immune checkpoint inhibitor therapy
For patients with metastatic renal cell carcinoma (mRCC) and progression during or after one to two prior lines of therapy, including one immune checkpoint inhibitor (ICI), tivozanib has efficacy, according to a study published online Sept. 13 in The Lancet to coincide with the annual meeting of the European Society for Medical Oncology, held from Sept. 13 to 17 in Barcelona, Spain.